These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26666380)

  • 21. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac sympathetic innervation assessed with (123)I-MIBG retains prognostic utility in diabetic patients with severe left ventricular dysfunction evaluated for primary prevention implantable cardioverter-defibrillator.
    García-González P; Fabregat-Andrés Ó; Cozar-Santiago P; Sánchez-Jurado R; Estornell-Erill J; Valle-Muñoz A; Quesada-Dorador A; Payá-Serrano R; Ferrer-Rebolleda J; Ridocci-Soriano F
    Rev Esp Med Nucl Imagen Mol; 2016; 35(2):74-80. PubMed ID: 26514320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of cardiac metaiodobenzylguanidine imaging and QRS duration in implantable cardioverter defibrillator patients with and without heart failure.
    Kawasaki M; Yamada T; Morita T; Furukawa Y; Tamaki S; Iwasaki Y; Kikuchi A; Kawai T; Seo M; Hirota Kida ; Sakata Y; Fukunami M
    Int J Cardiol; 2019 Dec; 296():164-171. PubMed ID: 31371118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heart rate variability density analysis (Dyx) for identification of appropriate implantable cardioverter defibrillator recipients among elderly patients with acute myocardial infarction and left ventricular systolic dysfunction.
    Jørgensen RM; Levitan J; Halevi Z; Puzanov N; Abildstrøm SZ; Messier MD; Huikuri HV; Haarbo J; Thomsen PE; Jons C;
    Europace; 2015 Dec; 17(12):1848-54. PubMed ID: 25755288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implantable cardioverter defibrillator for primary prevention in patients with severe ventricular dysfunction awaiting heart transplantation.
    Cantero-Pérez EM; Sobrino-Márquez JM; Grande-Trillo A; Lage-Gallé E; Rangel-Sousa D; Esteve-Ruiz IM; Martínez-Martínez A
    Transplant Proc; 2013; 45(10):3659-61. PubMed ID: 24314988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heart rate turbulence predicts ICD-resistant mortality in ischaemic heart disease.
    Marynissen T; Floré V; Heidbuchel H; Nuyens D; Ector J; Willems R
    Europace; 2014 Jul; 16(7):1069-77. PubMed ID: 24196450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function.
    Nagahara D; Nakata T; Hashimoto A; Wakabayashi T; Kyuma M; Noda R; Shimoshige S; Uno K; Tsuchihashi K; Shimamoto K
    J Nucl Med; 2008 Feb; 49(2):225-33. PubMed ID: 18199625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.
    Khazanie P; Hellkamp AS; Fonarow GC; Bhatt DL; Masoudi FA; Anstrom KJ; Heidenreich PA; Yancy CW; Curtis LH; Hernandez AF; Peterson ED; Al-Khatib SM
    J Am Heart Assoc; 2015 Aug; 4(8):e002061. PubMed ID: 26251283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of sudden cardiac death in chronic heart failure patients with reduced ejection fraction by ADMIRE-HF risk score and early repolarization pattern.
    Ikeda-Yorifuji I; Yamada T; Tamaki S; Morita T; Furukawa Y; Iwasaki Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Fukuhara E; Abe M; Nakamura J; Fukunami M
    J Nucl Cardiol; 2020 Jun; 27(3):992-1001. PubMed ID: 30761485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials.
    Jacobson AF; Lombard J; Banerjee G; Camici PG
    J Nucl Cardiol; 2009; 16(1):113-21. PubMed ID: 19152136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incremental prognostic value of myocardial neuroadrenergic damage in patients with chronic congestive heart failure: An iodine-123 meta-iodobenzylguanidine scintigraphy study.
    Giovanni S; Stefano M; Teresa SM; Margherita C; Giovanni B; Umberto P; Paola P; Giacomo C; Pierfranco D; Alfonso G; Riccardo C; Claudio M
    J Nucl Cardiol; 2020 Oct; 27(5):1787-1797. PubMed ID: 30377997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification in heart failure using ¹²³I-MIBG.
    Currie GM; Iqbal B; Wheat JM; Wang L; Trifunovic M; Jelinek HF; Kiat H
    J Nucl Med Technol; 2011 Dec; 39(4):295-301. PubMed ID: 21969356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy.
    Solomon SD; Foster E; Bourgoun M; Shah A; Viloria E; Brown MW; Hall WJ; Pfeffer MA; Moss AJ;
    Circulation; 2010 Sep; 122(10):985-92. PubMed ID: 20733097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Outcomes With Cardiac Resynchronization Therapy in Patients With Mild Heart Failure With Moderate Renal Dysfunction.
    Daimee UA; Moss AJ; Biton Y; Solomon SD; Klein HU; McNitt S; Polonsky B; Zareba W; Goldenberg I; Kutyifa V
    Circ Heart Fail; 2015 Jul; 8(4):725-32. PubMed ID: 26038537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of spontaneous reverse remodeling in mild heart failure patients with left ventricular dysfunction.
    Brenyo A; Barsheshet A; Kutyifa V; Ruwald AC; Rao M; Zareba W; Pouleur AC; Knappe D; Solomon SD; McNitt S; Huang DT; Moss AJ; Goldenberg I
    Circ Heart Fail; 2014 Jul; 7(4):565-72. PubMed ID: 24786217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients.
    Boogers MJ; Borleffs CJ; Henneman MM; van Bommel RJ; van Ramshorst J; Boersma E; Dibbets-Schneider P; Stokkel MP; van der Wall EE; Schalij MJ; Bax JJ
    J Am Coll Cardiol; 2010 Jun; 55(24):2769-77. PubMed ID: 20538172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac
    Verschure DO; de Groot JR; Mirzaei S; Gheysens O; Nakajima K; van Eck-Smit BLF; Aernout Somsen G; Verberne HJ
    Int J Cardiol; 2017 Dec; 248():403-408. PubMed ID: 28847545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.